



Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023

July 6, 2023

Three poster presentations to highlight clinical and preclinical data across Athira's pipeline of neuroprotective therapeutic candidates

BOTHELL, Wash., July 06, 2023 (GLOBE NEWSWIRE) -- [Athira Pharma, Inc.](#) (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that three poster presentations will be delivered in-person at the upcoming [Alzheimer's Association International Conference \(AAIC\)](#) 2023, to be held July 16 – 20, 2023, virtually and in Amsterdam, Netherlands. The presentations will highlight data from clinical and preclinical research of fosgonimeton in Alzheimer's disease, and preclinical data of ATH-1105 in models of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

AAIC Presentation Details:

Title: Fosgonimeton, a small-molecule positive modulator of the HGF/MET system, attenuates amyloid-beta-mediated toxicity in primary neuron cultures

Session: P2-05 Basic Science and Pathogenesis: Molecular and Cell Biology

Poster Number: 80009

Date/Time: Monday, July 17, 2023: 8:45 AM – 4:15 PM CEST

Presenter: Sherif Reda, PhD, Associate Director, Discovery Biology, Athira Pharma

Title: Biomarker analyses from the phase 2, randomized, placebo-controlled ACT-AD and open-label extension clinical trials of fosgonimeton in patients with mild-to-moderate Alzheimer's disease

Session: P4-06 Biomarkers: Biomarkers (non-neuroimaging)

Poster Number: 79759

Date/Time: Wednesday, July 19, 2023: 8:45 AM – 4:15 PM CEST

Presenter: Hans Moebius, MD, PhD, Chief Medical Officer, Athira Pharma

Title: ATH-1105, a small-molecule positive modulator of the HGF/MET system, is neuroprotective and attenuates TDP-43 protein pathology in ALS and frontotemporal dementia-relevant preclinical models

Session: P4-05 Basic Science and Pathogenesis: Molecular and Cell Biology

Poster Number: 80041

Date/Time: Wednesday, July 19, 2023: 8:45 AM – 4:15 PM CEST

Presenter: Jewel Johnston, PhD, Director, In Vivo Pharmacology, Athira Pharma

Full abstracts will be available to registered AAIC attendees. Access more information about AAIC 2023 [here](#).

About Athira Pharma, Inc.

Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates targeting the HGF/MET neurotrophic system for Alzheimer's and Parkinson's disease, Dementia with Lewy bodies, and amyotrophic lateral sclerosis (ALS). For more information, visit www.athira.com. You can also follow Athira on [Facebook](#), [LinkedIn](#) and [@athirapharma](#) on [Twitter](#) and [Instagram](#).

Forward-Looking Statements

This communication contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: product candidates as a potential treatment for Alzheimer's disease, Parkinson's disease, Dementia with Lewy bodies, and other neurodegenerative diseases, such as amyotrophic lateral sclerosis; Athira's platform technology and potential therapies; future development plans; expectations regarding the potential efficacy and commercial potential of Athira's product candidates; and Athira's ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "on track," "would," "expect," "plan," "believe," "intend," "pursue," "continue," "suggest," "potential," and other similar expressions, among others. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the data for our product candidates from our preclinical and clinical trials not supporting the safety, efficacy and tolerability of our product candidates; cessation or delay of Athira's development of product candidates may occur; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for product candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; the impact of the COVID-19 pandemic on Athira's business, research and clinical development plans and timelines, and the regulatory process for Athira product candidates; Athira may not be able to recruit sufficient patients for its clinical trials; the outcome of legal proceedings that have been or may in the future be instituted against us and certain of our directors and officers; clinical trials may not demonstrate safety and efficacy of any of Athira's product candidates; possible negative interactions of Athira's product candidates with other treatments; Athira's assumptions regarding the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets; the impact of competition; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira's clinical development plans as a result of the COVID-19 pandemic, which

could further delay development timelines; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athira's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

Investor & Media Contact

Julie Rathbun

Athira Pharma

Julie.rathbun@athira.com

206-769-9219